Most people who respond well to stem cell therapy for knee osteoarthritis experience benefits lasting two to seven years, though the range varies widely depending on the severity of arthritis, the type of cells used, and individual healing factors. Some patients notice relief fading after 18 to 24 months, while others report meaningful improvement five years or more after a single injection.
That wide window exists because stem cell therapy isn’t a standardized procedure the way a knee replacement is. The source of cells, the preparation method, your age, your weight, and how much cartilage damage you started with all shape the outcome. Here’s what the evidence actually shows.
What the Cells Do Inside Your Knee
Stem cells injected into a knee joint don’t simply become new cartilage. The reality is more nuanced. Mesenchymal stem cells (the type used in knee injections) work through two main pathways. First, they release a cocktail of growth factors, signaling molecules, and anti-inflammatory compounds that calm the joint environment, reduce pain, and recruit your body’s own repair cells to the damaged area. This is called paracrine signaling, and it accounts for much of the early relief patients feel.
Second, under the right conditions, stem cells can differentiate into cartilage-producing cells. But preclinical research shows that injecting cells alone often slows cartilage breakdown rather than rebuilding what’s already lost. True cartilage regeneration appears to require additional support, such as growth factor supplements or specialized scaffolds that give cells a structure to build on. This distinction matters for setting expectations: stem cell therapy is more likely to improve pain and function than to restore your knee to its 25-year-old state.
How Arthritis Severity Affects Duration
The stage of your osteoarthritis is one of the strongest predictors of how long results will last. Doctors grade knee arthritis on the Kellgren-Lawrence (KL) scale from 1 (minimal) to 4 (severe, bone-on-bone). Most clinical studies have focused on patients with KL grades 1 through 3, and the pattern is consistent: earlier-stage arthritis responds better and longer.
One study that separated results by grade found noticeably greater improvement in grade 2 knees compared to grade 3. Patients with grade 1 or 2 arthritis generally needed fewer treatment sessions to reach peak benefit, while those with grade 3 or 4 required more injections and saw smaller overall gains. If you have mild to moderate arthritis, you’re in the group most likely to land on the longer end of that two-to-seven-year window. If you have advanced bone-on-bone disease, the therapy may still reduce pain, but the effect tends to be shorter-lived and less dramatic.
Bone Marrow vs. Fat-Derived Cells
The two most common cell sources for knee injections are bone marrow aspirate concentrate (BMAC), drawn from your hip bone, and microfragmented adipose tissue (MFAT), harvested from body fat through a small liposuction procedure. BMAC has the longer clinical track record. MFAT has been proposed as a potentially better option because fat tissue contains a higher concentration of stem cells per volume.
However, there is no high-level evidence yet showing that one source outperforms the other. A randomized controlled trial comparing single injections of BMAC and MFAT is underway, tracking pain scores and knee function at 2, 6, and 12 months. Even the researchers behind that trial acknowledge that 12 months of follow-up may not be long enough to see meaningful differences in how the two approaches hold up over time. For now, the choice between bone marrow and fat-derived cells comes down to your provider’s experience and preference rather than clear superiority data.
When Repeat Injections Are Needed
If an initial treatment works well, many patients consider a repeat injection once benefits begin fading, which for some people happens around the 18- to 24-month mark. There’s no fixed schedule. The timing depends on how your symptoms evolve.
Related research on platelet-rich plasma (PRP) injections, which share some biological overlap with stem cell therapy, offers useful context on treatment frequency. A longitudinal study found that four injections yielded the highest overall response rate at about 85%, with early-stage patients reaching peak relief after four sessions and advanced-stage patients needing five. Beyond that optimal number, additional injections didn’t produce further gains. While PRP and stem cell injections aren’t identical, the principle likely applies: there’s a ceiling to how much benefit repeated treatments can add, and that ceiling is lower for more damaged knees.
The Recovery Timeline
The injection itself is an outpatient procedure. Most patients resume light daily activities within one to two days. The first 72 hours involve a deliberate rest period, during which localized soreness, swelling, and mild discomfort are normal. This early inflammation is actually part of the process: it’s your body’s initial response to the injected cells.
Weeks one through six are considered the activation phase, when cellular repair activity ramps up and the foundation of tissue rebuilding begins. During this window, you’ll want to avoid anti-inflammatory medications like ibuprofen or naproxen. These drugs interfere with the signaling pathways that guide stem cells toward repair. Acetaminophen (Tylenol) and ice packs are the recommended alternatives for managing discomfort. The core tissue-building phase extends from roughly week one through week twelve, with gradual improvements in pain and function accumulating over that period. Full results from a single injection often aren’t apparent until three to six months out.
What It Costs
Stem cell injections for knees typically run between $5,000 and $10,000 per treatment. Insurance generally does not cover the procedure, and Medicare won’t pay for unproven stem cell therapies (though it does cover established bone marrow transplants for other conditions). That out-of-pocket cost is a significant factor when weighing whether to pursue initial treatment or repeat injections.
The Regulatory Landscape
As of late 2025, stem cell therapy for knees is not FDA-approved. The FDA requires formal premarket review for high-risk stem cell therapies, and in late 2024, the agency won a key court case confirming its authority to regulate unproven treatments. The U.S. Supreme Court declined to revisit that decision in October 2025. Despite this, an estimated 2,750 stem cell clinics across the country offer unapproved injections for orthopedic conditions and other uses.
The FDA released new draft guidance in September 2025 outlining accelerated review pathways for regenerative medicine therapies, which could eventually bring some stem cell treatments through formal approval. But right now, clinics offering knee injections are operating in a space where the science is promising, the regulation is tightening, and the long-term data is still catching up. If you’re considering treatment, the quality and transparency of the clinic matters enormously. Ask what cell source they use, how they process it, and what outcome data they can share from their own patients.